Themis Medicare profit drops 96% to ₹1.14 crore
The pharmaceutical company reported a sharp decline in annual net profit for FY26, down from ₹29.83 crore in the prior year.
What's new
- Annual net profit fell to ₹1.14 cr from ₹29.83 cr in the previous year.
- The board recommended a final dividend of ₹0.50 per share.
- Total dividend payout amounts to approximately ₹4.6 cr.
Why this matters
The massive profit contraction is the primary takeaway from these audited results. While the dividend provides some return to shareholders, the earnings decline suggests significant pressure on the bottom line.
What we're watching
- Management commentary on the factors behind the profit collapse.
- Whether margins recover in the coming quarters.
- The impact of the dividend payout on cash reserves.
The full read
Themis Medicare closed FY26 with a sharp decline in profitability. Consolidated net profit for the year ended March 31, 2026, dropped to ₹1.14 crore, a steep fall from the ₹29.83 crore reported in the previous year. Despite the earnings slump, the board recommended a final dividend of ₹0.50 per share. This payout will cost the company approximately ₹4.6 crore. These audited figures are backward-looking and represent the final accounting for the fiscal year. The scale of the profit decline is the central issue for investors to consider as they assess the company's performance heading into the new fiscal cycle.
Questions answered
- How much did Themis Medicare's profit change year-over-year?
- Net profit fell from ₹29.83 crore in the previous year to ₹1.14 crore for the fiscal year ended March 31, 2026.
- What dividend did the board declare?
- The board recommended a final dividend of ₹0.50 per share, which totals approximately ₹4.6 crore.
- Is this a routine filing?
- Yes, this is a standard procedural disclosure of audited annual results and dividend recommendations following the close of the financial year.